<DOC>
	<DOCNO>NCT02024529</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double-blind study 500 patient osteoarthritis ( OA ) knee pain randomized Ampion placebo follow 20 week . The clinical effect treatment OA pain evaluate clinic visit 6 , 12 , 20 week use WOMACÂ® osteoarthritis Index Patient 's Global Assessment disease severity ( PGA ) . Safety assess record adverse event , concomitant medication , physical examination , vital sign clinical laboratory test .</brief_summary>
	<brief_title>AP-004-A Randomized , Controlled Study Evaluate Efficacy Safety Intra-articular Ampion Osteoarthritis Pain Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Clinical diagnosis radiological evidence symptomatic osteoarthritis knee Moderate severe pain Other condition knee , e.g. , crystal arthropathy , septic necrosis , joint replacement , major injury within 12 month prior screen , tense effusion Requires ongoing treatment intraarticular pain medication systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>